First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease.

CONCLUSION: At MBC-11 doses that were well tolerated, substantial reductions in metabolic activity of bone-associated cancer cells provide a foundation for further disease-directed efficacy studies.
PMID: 30413669 [PubMed - as supplied by publisher]

Source: The Oncologist - November 9, 2018 Category: Cancer & Oncology Authors: Zinnen SP, Karpeisky A, Von Hoff DD, Plekhova L, Alexandrov A Tags: Oncologist Source Type: research